Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

• Status: Unknown status
• Trial end date: 2020-06-17
• Target enrollment: 0
• Participant gender: All

Summary

This pilot randomized controlled trial aims to evaluate the feasibility for safety examination of continued metformin therapy in patients with type 2 diabetes (T2D) following invasive coronary angiography. Metformin will be continued until coronary angiography.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Saskatchewan
• Treatments: Metformin

Criteria

Inclusion Criteria:

1. Age ≥ 18 years

2. On metformin therapy

3. Angiography for ACS or elective non-ACS related indications

4. Informed consent received

Exclusion Criteria:

1. Cardiogenic shock prior to randomization

2. Cardiac arrest prior to randomization

3. Established severe CKD (eGFR<30, or on dialysis)

4. Chronic liver disease

5. Need for CABG within 48 hours of hospitalization

6. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated